Registry of Patients Prescribed Anticoagulation

Overview

About this study

The purpose is to create a registry of patients at Mayo Clinic who are prescribed the new novel anticoagulation therapy with either rivaroxaban, dabigatran, apixaban, oe edoxaban to allow post marketing survelliance with particular attention to cancer patients treated with novel anticoalants which in marketing studies the patient numbers were small. We also want to compare efficacy and safety of novel anticoagulants to "traditional" anticoagulants such as warfarin and low molecular weight heparin (LMWH) and therefore to register patients treated with this type of anticoagulation to our registry too.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • VTE seen at Thrombophilia Clinic and treatment with anti-coagulant is started within 14 days of VTE diagnosis date.

Exclusion Criteria:

  • Patients already on anticoagulation for other reasons or enrolled into anticoagulation clinical trials.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Waldemar Wysokinski, M.D., Ph.D.

Contact us for the latest status

Contact information:

Waldemar Wysokinski M.D., Ph.D.

(507) 668-2151

Wysokinski.Waldemar@mayo.edu

More information

Publications

  • To assess the outcome of direct oral anticoagulants (DOACs), specifically Xa inhibitors: rivaroxaban and apixaban, for the treatment of venous thromboembolism (VTE) of atypical location (VTE-AL), portal, mesenteric, hepatic, splenic, gonadal, renal, and cerebral veins, prospectively collected data of Mayo Thrombophilia Clinic Registry were used. Read More on PubMed
  • The purpose of this study is to evaluate the efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy, given the paucity of clinical data with the use of direct Xa inhibitors in this high-risk population. Read More on PubMed

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20315023

Mayo Clinic Footer